Reboxetine, )-2-[(RS)-alpha-(2-ethoxyphenoxy)benzyl]morpholine methane
sulphonate, is a racemic compound and consists of a mixture of the (R,
R)- and (S,S)-enantiomers. In this study, brain and plasma levels of b
oth enantiomers were determined in mice and rats after oral administra
tion of reboxetine at doses (1.1 mg/kg, mouse; 20 mg/kg, rat) twice th
e respective ED(50) values in the antireserpine test. Plasma and brain
concentrations of each enantiomer were measured up to 6 h postdosing
using an HPLC method with fluorimetric detection after derivatization
with a chiral agent (FLEC). In mice and rats, brain and plasma levels
of the (R,R)-enantiomer were always higher than those of the (S,S)-ena
ntiomer. After normalization for dose, the mean AUC(0-tz) values of bo
th the (R,R)- and (S,S)-enantiomers in mouse brain were about 23 and 3
2 times higher than in rat brain, respectively. In plasma, the correct
ed mean AUC(0-tz) values were about 5 (R,R) and 10 (S,S) times higher
in mice than in rats. These results provide evidence for the higher bi
oavailability and/or lower clearance of both enantiomers in mice than
in rats, and for a higher penetration of both enantiomers into mouse b
rain compared to rat brain. (C) 1995 Wiley-Liss, Inc.